"Albumin-Bound Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An injectable formulation of albumin-bound paclitaxel NANOPARTICLES.
| Descriptor ID |
D000068196
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777.500 D02.455.849.291.850.777.500 D12.776.034.073
|
| Concept/Terms |
Albumin-Bound Paclitaxel- Albumin-Bound Paclitaxel
- Albumin Bound Paclitaxel
- Paclitaxel, Albumin-Bound
- Protein-Bound Paclitaxel
- Paclitaxel, Protein-Bound
- Protein Bound Paclitaxel
|
Below are MeSH descriptors whose meaning is more general than "Albumin-Bound Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Albumin-Bound Paclitaxel".
This graph shows the total number of publications written about "Albumin-Bound Paclitaxel" by people in this website by year, and whether "Albumin-Bound Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Albumin-Bound Paclitaxel" by people in Profiles.
-
SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC. Int J Biol Sci. 2022; 18(3):911-922.
-
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. Cancer Chemother Pharmacol. 2019 10; 84(4):669-677.
-
Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett. 2017 09 10; 403:296-304.
-
CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come. Clin Cancer Res. 2015 May 01; 21(9):1975-7.
-
Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer. 2014 Aug; 14(4):228-34.
-
Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Ther. 2013 Apr; 29(3):360-2.
-
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer. 2010 Feb; 10(1):81-6.
-
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 01; 116(1):155-63.
-
Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol. 2008 Nov; 126(11):1605-6.
-
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005 Sep 01; 23(25):6019-26.